Mayo Clinic Study: Shorter Cancer Treatments Cut Side Effects While Preserving Cure Rates

A new Mayo Clinic study has found that a shortened, less intense course of radiation and chemotherapy after minimally invasive surgery for HPV-positive oropharyngeal squamous cell carcinoma (HPV+OPSCC) significantly reduces toxicity while maintaining high cure rates. The findings were published in The Lancet Oncology.

“This is a game-changer for patients,” said Daniel Ma, M.D., senior author of the study and head and neck radiation oncologist at Mayo Clinic Comprehensive Cancer Center. “We’ve significantly reduced the burden of long-term side effects without compromising the effectiveness of the treatment. This shorter, less intensive regimen allows patients to return to their lives more quickly and with a better quality of life.”

Traditional treatments for HPV-related oropharyngeal cancer usually involve seven weeks of daily radiation with chemotherapy, or surgery followed by six weeks of radiation and chemotherapy. While effective, these regimens often cause long-term side effects such as jawbone failure, dry mouth, altered taste, and difficulty swallowing. “These greatly affect the quality of life for patients, many of whom are young, in their 40s and 50s,” Dr. Ma noted.

In the phase 3 randomized trial, researchers compared standard therapy to a new approach: minimally invasive transoral surgery followed by a two-week course of gentler radiation therapy, known as de-escalated adjuvant radiotherapy (DART). The DART regimen delivers roughly half the standard radiation dose and only one-fifth of the chemotherapy typically given.

The study demonstrated that the less intensive regimen significantly reduced both severe (grade 3 or higher) and moderate (grade 2) toxicities. Patients experienced fewer adverse events and an improved symptom burden after treatment. Importantly, disease control rates for intermediate-risk patients were comparable to the standard regimen.

For high-risk patients — defined as those with five or more lymph nodes involved or disease extending outside of lymph nodes — the standard treatment offered slightly better disease control. Researchers believe this may be due to chemotherapy-related factors rather than radiation intensity. As a result, they recommend that these patients continue with the full six-week regimen.

The trial included 228 patients treated at Mayo Clinic locations in Minnesota and Arizona. According to the researchers, this represents the largest published cohort of patients undergoing postsurgical de-escalation to date.

Mayo Clinic researchers also plan to explore the use of biomarkers such as circulating DNA to better identify which patient populations could benefit most from the shorter treatment strategy.